

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Pediatrics

**ESPS manuscript NO:** 27255

**Title:** Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction

**Reviewer's code:** 00506481

**Reviewer's country:** India

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2016-05-20 14:06

**Date reviewed:** 2016-05-26 16:14

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

The study has been well conceived and the methods have been followed carefully; the results are very encouraging and need to be shared with the scientific community. A few corrections have been made and shown as green highlight; in some instances 'striethrough' was done to correct the manuscript. In this manuscript titled Potential carrier priming effect in Australian infants after 7vPCV introduction, the authors have reported four VT-IPD cases occurring < 2 weeks after one carrier primed dose of 7vPCV while only one case occurred 2-9 weeks later. The observation with the non-VT-IPD cases after one carrier primed dose of 7vPCV was that two cases were detected within two weeks, whereas seven cases occurred within 2-9 weeks. These findings suggest a substantial level of protection from VT-IPD occurring from two weeks after carrier-primed dose of 7vPCV. The benefit from just one dose of 7vPCV is most likely through enhanced immunity from carrier priming effect. If this is proven, an adjusted 2-dose schedule (where the first PCV is not given until after DTPa) may be sufficient and cost-effective.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Pediatrics

**ESPS manuscript NO:** 27255

**Title:** Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction

**Reviewer's code:** 00506472

**Reviewer's country:** Greece

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2016-05-20 14:06

**Date reviewed:** 2016-05-27 05:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

It is an interesting descriptive analysis investigating evidence for clinical protection in infants after one dose of the 7-valent pneumococcal conjugate vaccine (7vPCV) as a result of possible prior carrier priming from Tdap vaccine administration. It provides evidence for efficacy of reduced PCV schedule if administered following Tdap vaccination. This is valuable especially for developing countries as saving cost. More studies are needed, as in this study few participants are included. 1. Material and Methods: More details needed from vaccine history of participated infants: number of Tdap doses administered prior to PCV dose, interval between last Tdap dose and PCV administration, age of single PCV dose administration. All the above parameters may impact the immunogenicity and efficacy of PCV dose. 2. Page 6, lines 5-6: "All cases  $\geq$  2 months old are presumed to receive DTPa". Please see the comment above. 3. Page 6, lines 7-8: "Due to strong evidence of cross protection with 6B, we considered 6A as vaccine type (VT)". Evidence of cross protection is not a condition that changes a pneumococcal serotype from non-vaccine type to vaccine type. Please define how the inclusion of 6B in vaccine types impact the results. 4. Page 10, lines 18-21:



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

“...involving 13-valent PCV demonstrated that the vaccine is effective in preventing vaccine-type pneumococcal, bacteraemia, and nonbacteraemic community-acquired pneumonia and vaccine-type IPD [24]”. Vaccine is not effective in nonbacteraemic community-acquired pneumonia. It has a low efficacy against all-cause pneumonia, due to the fact that a large proportion of all-cause pneumonia is pneumococcal. Please correct. 5. Language needs minor revision.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Pediatrics

**ESPS manuscript NO:** 27255

**Title:** Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction

**Reviewer's code:** 00506492

**Reviewer's country:** Iran

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2016-05-20 14:06

**Date reviewed:** 2016-05-29 17:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

In this retrospective clinical protection study, priming effects of DTPa on one dose 7vPCV injected infants was examined. In general a new approach to PCV is recommended and the data were well examined for a subject matter which worth looking into. There are, however, some points for clarification: 1-With a proper reference please clarify invasive and noninvasive PD. 2-Tables 1 & 2, it is not very clear in the legend how the p value was determined. Please explain the statistical comparison in the legend as written in the text. 3-Page 10 line 6, it is third "world" not "word" 4-All cases  $\geq 2$  months old "were" not "are" presumed. 5-Was this presumption based on the questionnaire or general national vaccination program. Please clarify on your assumption. 6-In the M & M, isolation of the serotypes contained in 7vPCV (4, 6B, 9V, 14, 18C, 19F, and 23F) was considered. Yet, no data is given about the serological types of the 5 VT-IPD in the study. This is an important point which must be given and discussed. Somehow, a revision of the discussion is needed where the status of PCV and PD in Australian is missing (before and after PCV) which would strengthened the discussion.